NEW YORK (GenomeWeb News) – Active Motif announced Thursday that it has acquired privately held genomics tools maker SwitchGear Genomics for an undisclosed price.
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – SwitchGear Genomics today said it has partnered with New England Biolabs to develop a new dual reporter assay system.
Cosmo Bio will distribute the LightSwitch Luciferase Assay System with marketing and technical support from SwitchGear.
BioCat will distribute the firm's LightSwitch Luciferase Assay System in select European countries.
Under the distribution agreement, SwitchGear will offer the reagent as a standalone product as well as part of its own LightSwitch Transfection Optimization kit.
The collaboration brings together SwitchGear's expertise in gene regulatory networks and Sigma-Aldrich's lentiviral technology and is expected to result in a genome-wide collection of target vectors.
The method combines Promega's HaloCHIP DNA-protein complex capture technology and SwitchGear's high-throughput promoter assays.
Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.
Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.
The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.
In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.